Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Corsair Gaming Q2 2026 Earnings Call - Raised Full-Year EBITDA Guidance on Record Margins and Cash Generation
Corsair Gaming delivered a quarter defined by margin expansion and cash generation rather than top-line growth. Q2 revenue dipped 2% year-over-year to $314.3 million as elevated memory pricing continu...
- Q2 gross margin hit a company record of 33.2%, with gross profit up 21% year-over-year to $104.3 million.
- Operating cash flow surged 148% to $74.8 million, with the first half of 2026 generating more cash than 2024 and 2025 combined.
- Corsair raised full-year 2026 adjusted EBITDA guidance by roughly $19 million to a midpoint of $126 million, driven by stronger organic momentum and the Trak Racer acquisition.
- +7 more takeaways
Applied Optoelectronics
Applied Optoelectronics delivered a fifth straight quarter of record results in Q2 2026, posting $191.9 million in revenue and returning to non-GAAP profitability. The numbers reflect a company caught...
- Q2 revenue hit a record $191.9 million, up 86% year-over-year and 27% sequentially, landing squarely within management guidance.
- The company returned to non-GAAP profitability with $5.5 million in net income, marking five consecutive profitable quarters and beating per-share estimates.
- Data center revenue surged 140% to $107.7 million, driven by a tenfold year-over-year jump in 800G transceivers and a fourfold increase in 400G units.
- +8 more takeaways
Universal Electronics Q2 2026 Earnings Call - Profitability Achieved on Lower Revenue Through Structural Cost Cuts and Leadership Transition
Universal Electronics delivered its second quarter of 2026 results in the middle of a quiet but decisive leadership handoff. Revenue contracted 25% year-over-year to $73.2 million as legacy video decl...
- Revenue contracted 25% year-over-year to $73.2 million, pressured by legacy video decline, European retail weakness, and delayed Connected Home growth.
- Profitability emerged despite lower sales, with adjusted non-GAAP EPS of $0.34, driven by structural cost cuts rather than a demand rebound.
- A one-time $5.1 million tariff recovery boosted Q2 results. Excluding this non-recurring item, the company still posted a profit on a leaner cost base.
- +9 more takeaways
Perdoceo Education Corporation Q2 2026 Earnings Call - Dividend Raised to $0.17 as St. Augustine Fuels Double-Digit Margin Growth and Full-Year EPS Surges to $3.10-$3.16
Perdoceo Education Corporation delivered a quarter defined by disciplined execution and the accelerating value creation of its health sciences acquisition. Net income climbed to $48 million, or $0.75 ...
- Perdoceo lifts the quarterly dividend to $0.17, marking the third consecutive increase since 2023. The board treats the payout as a growing pillar of capital allocation, backed by $334.8 million in cash and robust operating cash flows that support sustainable returns.
- Second-quarter net income hit $48 million, up from $41 million in the prior year, while revenue climbed 1.8% to $213.4 million. The company delivers clear operating leverage, expanding adjusted operating income by 4.4% while selectively reinvesting in marketing and student success teams.
- The University of St. Augustine for Health Sciences proves the acquisition strategy works. Revenue surged 10.2% to $40.5 million, and adjusted operating income nearly doubled to $10.7 million. The health sciences unit now hosts 4,200 students and drives the portfolio's highest growth rates.
- +8 more takeaways
PAR Technology Q2 2026 Earnings Call - Platform-Driven ARR Acceleration and Raised Full-Year Profitability Guidance
PAR Technology delivered a quarter that quietly reinforces the math behind its platform thesis. Revenue climbed 19% to $133 million while adjusted EBITDA jumped $9 million year-over-year to $14.3 mill...
- Revenue and profitability accelerated in Q2. Total revenue reached $133 million, up 19% year-over-year, while adjusted EBITDA climbed $9 million to $14.3 million, beating guidance and marking the sixth consecutive quarter of sequential profit growth.
- ARR momentum is phasing higher. Annualized recurring revenue closed at $338 million, representing 17% total growth and 12.3% organic growth. Management expects a meaningful second-half ramp driven by tier-one implementations and mid-tier pipeline conversion.
- The platform strategy is compounding. Nearly 100% of new deals now bundle multiple products, doubling contract lengths versus point solutions and pushing the three-year blended ARPU CAGR to 8%.
- +7 more takeaways
Sprout Social Q2 2026 Earnings Call - AI Monetization and Enterprise Shift Power Margin Expansion Despite 20 Headcount Cut
Sprout Social is executing a deliberate pivot that favors scale over sprawl. Revenue climbed 10.8 percent to $123.8 million, but the real signal sits in the customer mix. Accounts contributing $30,000...
- Revenue grew 10.8 percent year-over-year to $123.8 million, with non-GAAP operating margin expanding 370 basis points to 12.9 percent.
- Customers contributing $30,000 or more in ARR now drive 61 percent of subscription revenue, up from 59 percent in mid-2022, with the segment growing 20 percent year-over-year.
- Multi-year contracts now represent nearly half of the contract mix, up from roughly one-third two years ago, supporting CRPO growth of 12.4 percent to $202.7 million.
- +7 more takeaways
Arrow Electronics Q2 2026 Earnings Call - Revenue and EPS Surge Past Guidance on Broad-Based Demand and Operating Leverage
Arrow Electronics delivered a quarter that defied the typical distribution playbook, posting $10 billion in revenue and $5.45 in non-GAAP EPS, both comfortably above management expectations. The resul...
- Revenue hit $10 billion, up 32% year-over-year, while non-GAAP EPS jumped 124% to $5.45, comfortably clearing management guidance.
- Operating margins expanded 120 basis points to 4%, fueled by disciplined expense control, lower interest costs, and structural operating leverage.
- Global Components drove $7.4 billion in sales, with book-to-bill ratios consistently above parity across all three regions and backlog visibility extending into the first half of 2027.
- +7 more takeaways
Shoulder Innovations Q2 2026 Earnings Call - Raised FY26 Revenue Guidance on 56% Growth and Accelerating Surgeon Adoption
Shoulder Innovations reported a second quarter that reads less like a typical orthopedic device cycle and more like a commercial engine firing on all cylinders. Revenue jumped 56 percent to $17.2 mill...
- Revenue surged 56% year-over-year to $17.2 million, driven by accelerating new surgeon onboarding and deeper utilization within the existing customer base.
- Full-year 2026 revenue guidance was raised to $67 million to $69 million, reflecting a 42% to 46% growth trajectory and signaling management’s high conviction in commercial execution.
- Gross margin expanded to 78.3%, supported by strong average selling prices and negotiated cost reductions, with management projecting sustained margin levels through year-end.
- +7 more takeaways
Blink Charging Co. Q2 2026 Earnings Call - Structural Margin Expansion and Cost Reset Target Q4 Breakeven
Blink Charging is shedding its growth-at-all-costs skin. The second quarter of 2026 reads less like a typical EV infrastructure update and more like a corporate restructuring in motion. Revenue guidan...
- Revenue guidance was cut to $83M-$90M after Blink walked away from unprofitable contracts and divested Envoy Technologies. Sequential revenue still rose 4.3% to $21.7M. Quality is replacing quantity.
- GAAP gross margin expanded 2,200 basis points to 38.9%. The jump came from shifting Level 2 production to contract manufacturers, optimizing hardware mix, and pricing owned charging sites more aggressively.
- Operating expenses fell 57% year-over-year to $14.7M. Compensation dropped 39% and G&A shrank to $1.8M. The restructuring is structural. Management will not reverse course.
- +7 more takeaways
Trevi Therapeutics Q2 2026 Earnings Call - $319 Million Cash Runway Extends Through 2030 as Sole Player Advances Chronic Cough Pipeline
Trevi Therapeutics closed the second quarter of 2026 with $319 million in cash and marketable securities, a balance sheet that comfortably funds its chronic cough development program through 2030. Man...
- Cash position stands at $319 million, extending operational runway through 2030 to fund IPF and non-IPF ILD development, the LAKE-2b RCC trial, and pre-commercial activities.
- OCEAN-1 phase III trial for IPF-related chronic cough launched in Q2, with OCEAN-2 phase III initiation targeted for Q3.
- LAKE-2b phase II-B trial for refractory chronic cough is enrolling across more than 200 global sites, with sample size re-estimation planned for Q4 at the 50% completion mark.
- +9 more takeaways